Dr Sehn talks to ecancer at EHA 23 about combining polatuzumab vedotin, a novel antibody-drug conjugate, with bendamustine and rituximab for patients whose lmyphoma has returned.

She outlines the design and construction of polatuzumab vedotin and discusses how the combination led to higher rates of complete response, longer progression free survival and better overall survival than BR alone.

For more on these results, watch Dr Sehn present the findings at a press session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.